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We report here that leptin can act as a negative
signal for the proliferation of human naturally
occurring Foxp3+CD4+CD25+ regulatory T
(Treg) cells. Freshly isolated Treg cells produced
leptin and expressed high amounts of leptin re-
ceptor (ObR). In vitro neutralization with leptin
monoclonal antibody (mAb), during anti-CD3
and anti-CD28 stimulation, resulted in Treg cell
proliferation, which was interleukin-2 (IL-2) de-
pendent. Treg cells that proliferated in the pres-
ence of leptin mAb had increased expression
of Foxp3 and remained suppressive. The phe-
nomena appeared secondary to leptin signaling
via ObR and, importantly, leptin neutralization
reversed the anergic state of the Treg cells, as
indicated by downmodulation of the cyclin-
dependent kinase inhibitor p27 (p27kip1) and
the phosphorylation of the extracellular-related
kinases 1 (ERK1) and ERK2. Together with the
finding of enhanced proliferation of Treg cells
observed in leptin- and ObR-deficient mice,
these results suggest a potential for therapeutic
interventions in immune and autoimmune
diseases.
INTRODUCTION
Thymus-derived, naturally occurring, regulatory T (Treg)
cells are a subset of T lymphocytes that constitutes about
5%–10% of peripheral CD4+ T cells. Treg cells constitu-
tively express the high-affinity interleukin-2 (IL-2) receptor
a chain CD25 and can inhibit effector T cell responses
in vitro and in vivo (Shevach, 2002; Sakaguchi, 2004;
Suri-Payer et al., 1998; Thornton and Shevach, 1998; Ng
et al., 2001). Treg cells express the forkhead family tran-
scription factor Foxp3, a key control gene for their devel-
opment and function (Shevach, 2002; Sakaguchi, 2004).
Given the importance of Treg cells in the mechanisms of
immune regulation and their protective role in severalImautoimmune conditions, there has been wide interest in
finding strategies that expand Treg cell numbers in the pe-
riphery (Kretschmer et al., 2005; Tang et al., 2004; Jiang
et al., 2003). However, technical difficulties including
hyporesponsiveness of freshly isolated Treg cells to T cell
receptor (TCR) stimulation in culture has hampered this
process (Thornton and Shevach, 1998; La Cava et al.,
2004). Nonetheless, murine and human Treg cell numbers
have been expanded in vitro up to 200-fold in the pres-
ence of high doses of IL-2 (Tang et al., 2004; Jiang et al.,
2003). These proliferated Treg cells continue to express
cell-surface molecules and intracellular markers consis-
tent with a regulatory phenotype and effectively suppress
in vitro proliferative responses to either anti-CD3 or alloge-
neic stimuli, in a fashion similar to naturally occurring Treg
cells (Tang et al., 2004; Jiang et al., 2003).
Leptin is a cytokine-like hormone structurally similar to
IL-6 and is involved in the control of food intake, metabo-
lism, and T cell function (Friedman and Halaas, 1998; La
Cava and Matarese, 2004). We report here that freshly iso-
lated human Treg cells constitutively expressed high
amounts of both leptin and the leptin receptor (ObR) and
that the leptin pathway can act as a negative signal for
the proliferation of Treg cells. These findings may partly ex-
plain why chronic leptin- and leptin-receptor deficiency
associate with increased susceptibility to infection and re-
sistance to autoimmunity (La Cava and Matarese, 2004;
Ikejima et al., 2005; Farooqi et al., 2002; Matarese et al.,
2002) and the increased risk of infection and reduced inci-
dence of autoimmunity in individuals with low leptin
(Matarese et al., 2002). These results may also suggest
new possibilities for leptin-based manipulation of the
Treg cells.
RESULTS
Human Treg Cells Express Higher Amounts of ObR
than Do CD4+CD25 Effector T Cells
Previous studies have shown that leptin receptor (ObR) is
expressed on CD4+ T cells and that it is able to switch
immune responses toward a T helper 1 (Th1) phenotype
(La Cava and Matarese, 2004). We sought to analyze the
expression of ObR on Treg cells and to correlate itsmunity 26, 241–255, February 2007 ª2007 Elsevier Inc. 241
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Treg Cell Proliferation Controlled by LeptinFigure 1. Human Treg Cells Express High ObR, and Leptin Neutralization Reverses Their Hyporesponsiveness
(A) Representative flow cytometry plot of human T cells stained for CD4, CD25, and Foxp3.
(B and C) Immunoblot analysis of sorted CD4+ T cells on the basis of their CD25 expression. Graphs show quantitation of Foxp3 and ObR with respect
to tubulin. One representative out of five independent experiments is shown.
(D) Proliferation of CD4+CD25+ Treg cells treated with recombinant human leptin (250 ng/ml) in the presence or absence of leptin mAb (10 mg/ml). The
data are shown as mean ± SD (n = 5, *p < 0.0001; **p < 0.01).
(E) Dose dependency of Treg cell proliferation induced by leptin mAb. Proliferation was measured after treatment with indicated doses of leptin mAb.
The data are shown as mean ± SD (n = 5).
(F) Proliferation of Treg cells induced by a fixed dose of leptin mAb in the presence of increasing concentration of recombinant leptin. The data are
shown as mean ± SD (n = 5).
(G) Proliferation of CD4+CD25 effector T cells treated with recombinant human leptin (250 ng/ml) in the presence or absence of leptin mAb (10 mg/ml).
The data are shown as mean ± SD (n = 5, *p < 0.01; **p < 0.01).
(H) Proliferation of CD4+CD25 effector T cells, Treg cells, and of both cell types in coculture in the presence or absence of leptin mAb (10 mg/ml). The
data are shown as mean ± SD (n = 5, *p < 0.01; **p < 0.0001).expression with Foxp3. CD4+CD25+ Treg cells and
CD4+CD25 effector T cells purified from human healthy
donors (Figure 1A, left) were analyzed for Foxp3 expres-
sion by FACS analysis and immunoblot (Figure 1A, right,
and Figure 1B, respectively). As expected, Treg cells
showed high amounts of Foxp3 protein whereas
CD4+CD25 did not show detectable amount of the pro-
tein in cell extracts (Figures 1A and 1B). Instead, ObR
was expressed on both freshly isolated cellular subsets,
although at significantly higher amounts (p < 0.001) in
Treg cells as compared to the CD4
+CD25 T cell effectors
(Figure 1C).
Leptin Neutralization Results in the Proliferation
of Human Treg Cells Stimulated with Anti-CD3
and Anti-CD28
Human Treg cells were hyporesponsive to anti-CD3 and
anti-CD28 stimulation (Figure 1D), in agreement with pre-
vious findings (Ng et al., 2001). Addition of exogenous
recombinant leptin to the cultures did not alter Treg cells
hyporesponsiveness (Figure 1D). However, addition of
neutralizing leptin monoclonal antibody (mAb) reversed
the hyporesponsiveness and promoted Treg cell prolifera-
tion (Figure 1D) in a dose-dependent fashion (Figure 1E).
Analogous results were observed with different leptin or242 Immunity 26, 241–255, February 2007 ª2007 Elsevier Inc.ObR-blocking antibodies (see Figure S1 in the Supple-
mental Data available online). Confirming specificity,
addition of exogenous recombinant leptin to anti-CD3-
and anti-CD28-stimulated Treg cells antagonized the
proliferation induced by leptin mAb (Figure 1D). More-
over, dose-dependent increase of the proliferation of
stimulated Treg cells in the presence of leptin mAb
(Figure 1E) was reversed by addition of increasing doses
of recombinant leptin (Figure 1F). Interestingly, leptin mAb
inhibited the proliferation of purified effector CD4+CD25
T cells, a phenomenon that was reversed by addition of
exogenous leptin (Figure 1G). Thus, neutralization of lep-
tin had opposite effects on effector CD4+CD25 T cells
and Treg cells—it inhibited proliferation on the former
lymphocyte subset (Figure 1G), whereas it promoted ex-
pansion of the latter subpopulation (Figure 1D). This ef-
fect was also evident morphologically, as formation of
cell clumps in the cultures of Treg cells stimulated with
anti-CD3 and anti-CD28 and leptin mAb, but not in the
cultures of Treg cells stimulated with anti-CD3 and anti-
CD28 in the absence of leptin mAb (data not shown).
Finally, in coculture experiments, Treg cells efficiently sup-
pressed the proliferation of CD4+CD25 T cells, and
leptin neutralization reversed the suppression by Treg
cells (Figure 1H).
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Treg Cell Proliferation Controlled by LeptinFigure 2. Human Treg Cells Exhibit Partial Suppressive Capacity upon Leptin-mAb-Induced Proliferation
(A) Proliferation of CD4+CD25 effector T cells, Treg cells, and of both cell types in coculture treated with recombinant human leptin (250 ng/ml) in the
presence or absence of leptin mAb (10 mg/ml). The data are shown as mean ± SD (n = 3, *p < 0.0001; **p < 0.01).
(B–I) Proliferative response (B–E) and CD25 expression analysis (F–I) of CFSE-labeled-CD4+CD25 effector T cells alone or in coculture with untreated
or leptin-mAb-treated unlabeled Treg cells. The thin line represents the isotype-matched negative control and the thick line represents the CD25 stain-
ing. One representative out of three independent experiments is shown (*p < 0.0001; **p < 0.01; ***p < 0.05, as compared with CD4+CD25CFSE+).Proliferated Treg Cells Have Partial Suppressive
Capacity that Attains Full Activity when They Enter
the Resting Phase
The suppressive capability of Treg cells in the presence of
leptin mAb was tested in coculture experiments of Treg
cells together with CD4+CD25 T cells. Addition of exog-
enous leptin did not affect suppression of Treg cells on
CD4+CD25 T cells (Figure 2A). In contrast, suppression
of proliferation was apparently abrogated in the presence
of leptin mAb (Figure 2A, gray columns). Concomitant ad-
dition of leptin together with the leptin mAb partly reduced
the anti-leptin-induced reversal of suppression, confirm-
ing specificity for leptin neutralization in the coculture
experiments (Figure 2A, gray columns).
To understand whether Treg cells during anti-leptin-in-
duced proliferation could exert suppressive capacity, we
performed coculture experiments with CFSE-labeled
CD4+CD25 T cells in the presence of unlabeled Treg cells
(Figures 2B–2E). As expected, Treg cells suppressed the
expansion of CD4+CD25 effectors (Figure 2D), and sup-
pression was partially maintained in the presence of leptin
mAb (Figure 2E)—albeit at a lower degree when compared
with untreated Treg cells (Figure 2D). This suggested that
Treg cells during anti-leptin-induced proliferation are par-
tially functional in terms of suppressive capability.
Moreover, the coculture experiments of Treg cells with
CD4+CD25 T cells, in the presence of leptin mAb, indi-
cated that the reversal of suppression (Figure 2A, gray col-
umns) was apparent only because CD4+CD25 effectors
were inhibited in part in their proliferation, as indicated
by the CFSE dilution (Figure 2E). Thus, the high amount
of [3H]thymidine incorporation in coculture of Treg cellsImwith CD4+CD25 T cells in the presence of leptin mAb
(Figures 1H and 2A) has to be ascribed to both Treg cell
proliferation and partly to CD4+CD25 T cells. These phe-
nomena were confirmed in terms of expression of the
activation marker CD25 on CFSE-labeled CD4+CD25
effector T cells. The anti-CD3 and anti-CD28 activation
induced a substantial upregulation of CD25 on the cell sur-
face (Figure 2F) and was significantly inhibited in the pres-
ence of Treg cells (Figure 2H). A significant reduction of
CD25 expression on effector T cells was observed in the
presence of anti-leptin-expanding Treg cells (even if at
lower extent when compared with untreated Treg cells)
(Figure 2I). In any case, the suppressive capacity of anti-
leptin-expanding Treg cells was diminished by about
40%, and a certain number of CD4+CD25 T cells was still
able to proliferate and divide (Figure 2E).
Next, we performed two-step experiments to address
whether anti-leptin-proliferated Treg cells in the resting
phase could retain their suppressive capacity over time.
8 days after the first expansion, stimulated Treg cells
were still suppressive for CD4+CD25 effector T cells in
in vitro coculture experiments (Figures S2A–S2C). Al-
though effector CD4+CD25 T cells cultured in the pres-
ence of leptin mAb proliferated upon restimulation and
did not suppress allogeneic CD4+CD25 T cells expan-
sion in coculture experiments (Figure S2B), the anti-
leptin-expanded Treg cells maintained their hyporespon-
siveness after restimulation and were capable of
suppressing proliferation of allogeneic CD4+CD25 effec-
tor T cells (Figure S2C). These data suggested that the
anti-leptin-proliferated Treg cells, once in the resting
phase, maintain their suppressive capacity over time.munity 26, 241–255, February 2007 ª2007 Elsevier Inc. 243
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Treg Cell Proliferation Controlled by LeptinFigure 3. Treg Cells Produce Leptin and Express High Amounts of ObR
(A) Proliferation of CD4+CD25 effector T cells, Treg cells, and of both cell types in coculture in three different serum- and leptin-free media in the
presence or absence of leptin mAb. The data are shown as mean ± SD (n = 6, *p < 0.01; **p < 0.001).
(B) Flow cytometry plot of BrdU incorporation of CD4+CD25 effector T cells, Treg cells, and of both cell types in coculture in serum-free medium
(X-VIVO), in the presence or absence of leptin mAb during anti-CD3 and anti-CD28 stimulation. One representative out of three independent exper-
iments is shown (*p < 0.05; **p < 0.001).
(C) Confocal microscopy of freshly isolated and 1 hr-stimulated Treg cells and CD4
+CD25 effectors stained for leptin (in green) and leptin receptor
(ObR) (in red). One representative out of three independent experiments is shown.
(D) Immunoblot for leptin on cell lysates from Treg cells and CD4
+CD25 effectors. The graph shows quantitation of leptin with respect to total ERK1/2.
One representative out of three independent experiments is shown.Leptin Production from Human Treg Cells
Leptin is present in media supplemented with human se-
rum, such as the medium used in our experiments (see Ex-
perimental Procedures). To test whether human Treg cells244 Immunity 26, 241–255, February 2007 ª2007 Elsevier Inc.could expand in the absence of leptin, we stimulated Treg
cells with anti-CD3 and anti-CD28 in three different types
of serum- and leptin-free media (Figure 3A). Under these
conditions, Treg cells maintained hyporesponsiveness
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Treg Cell Proliferation Controlled by Leptineven in the absence of exogenous leptin. Surprisingly,
addition of leptin mAb to the cultures resulted in Treg cell
proliferation (Figure 3A). This finding was also confirmed
by BrdU incorporation in serum-free medium cultures
(Figure 3B). This finding suggests the possibility that leptin
may be produced by Treg cells in a fashion similar to the
production of leptin by CD4+ T cells and monocytes in
multiple sclerosis (Sanna et al., 2003; Matarese et al.,
2005). To test this possibility, we examined leptin and
ObR expression on Treg cells and CD4
+CD25 T cells.
Both freshly isolated Treg cells and CD4
+CD25 T cells
stained positive for leptin and ObR, with different intensity
patterns (Figure 3C). Moreover, after 1 hr culture, Treg cells
showed higher leptin production than did CD4+CD25 T
cells, and this tendency was maintained during anti-CD3
and anti-CD28 stimulation, both in the presence and in
the absence of leptin mAb (Figure 3C). Parallel quantita-
tion by immunoblotting analysis for leptin on cell lysates
confirmed the difference (Figure 3D). Indeed, the presence
of a basal production of leptin increased significantly after
anti-CD3 and anti-CD28 stimulation (Figure 3D), and Treg
cells always produced more leptin than did CD4+CD25
T cells (Figure 3D). Interestingly, leptin neutralization in-
duced a compensatory leptin production and ObR upre-
gulation in both Treg cells and CD4
+CD25 T cells, and
again, to a higher amount in the Treg cells (Figures 3C
and 3D). These results were confirmed at 12 hr by confo-
cal microscopy and immunoblotting studies (data not
shown). Additionally, to address the capacity of Treg cells
and CD4+CD25 T cells to secrete leptin, we performed
a human leptin-specific ELISA (see Experimental Proce-
dures) and confocal microscope analysis at different
time points (12 hr and 36 hr) on culture supernatants
(Figure S3). At 12 hr, the secretion of leptin was similar in
both Treg cells and CD4
+CD25 T cells, whereas at 36 hr
the amount of leptin secreted was significantly higher
in the Treg cells, either unstimulated or treated with
anti-CD3 and anti-CD28 plus leptin mAb (Figure S3). The
finding was confirmed by the observation of a reduced
content of leptin in Treg cells at 36 hr (Figure S3) in confocal
microscopy and immunoblotting studies on cell lysates
(data not shown). Finally, these results on leptin secretion
were also confirmed by immunoblotting for leptin on cul-
ture supernatants (data not shown). Thus, these results
suggest the presence of an autocrine loop of leptin secre-
tion by Treg cells controlling their hyporesponsiveness.
Leptin-mAb-Induced Proliferation of Treg Cells Is IL-2
Dependent, and IL-2-Supported Expansion
of Treg Cells Is Not Affected by Leptin
To test whether the leptin-mAb-induced proliferation of
Treg cells was IL-2 dependent, we evaluated the effects
of IL-2 neutralization on the Treg cell proliferative re-
sponses and IL-2 production. Addition of human IL-2-neu-
tralizing mAb enhanced the inhibitory effects of leptin mAb
treatment on the CD4+CD25 T cell proliferation and IL-2
secretion (Figures 4A and 4B, white bars). IL-2 mAb re-
duced both Treg cell proliferation and IL-2 production in-
duced by the neutralization of leptin (Figures 4A and 4B,Imblack bars). Moreover, the apparent reversal of suppres-
sion in coculture experiments resulting from anti-leptin-in-
duced Treg cells proliferation was inhibited by anti-IL-2
(Figures 4A and 4B, gray bars). IL-2 secretion was evalu-
ated via CTLL-2 proliferation (Figure 4B). These results
were also confirmed by intracellular staining for IL-2 in
FACS analysis and ELISA (Figure S4).
Next we compared IL-2-induced proliferation versus
anti-leptin-induced proliferation on Treg cells. Addition of
exogenous IL-2 reversed Treg cells unresponsiveness
upon anti-CD3 and anti-CD28 stimulation (Figure 4C,
left), as expected. Of interest, IL-2-induced proliferation
was less than that observed upon leptin blockade
(Figure 4C, left). To also address whether anti-leptin treat-
ment affected the ability of Treg cells to proliferate in the
presence of IL-2 but in the absence of TCR stimulation,
we measured the proliferation of unstimulated Treg cells
cultured with leptin mAb or IL-2 and anti-leptin plus IL-2.
No proliferation was observed in the absence of TCR en-
gagement in all the above conditions (Figure 4C, left). Fi-
nally, we tested whether leptin could inhibit IL-2-induced
expansion of Treg cells. The anti-proliferative effect of in-
creasing doses of recombinant leptin on Treg cell prolifer-
ation induced by IL-2 was not significant (Figure 4C, right),
suggesting that IL-2 signaling may be independent and
dominant of the leptin-mediated inhibitory effects on the
cell proliferation.
Treg Cells Expandedwith LeptinmAbHave Increased
Expression of Foxp3
We next addressed whether leptin neutralization could af-
fect the amount of Foxp3 in Treg cells. Foxp3 expression
was evaluated after leptin neutralization at 1 hr and 12 hr
during anti-CD3 and anti-CD28 stimulation. As shown in
Figure 4D, Foxp3 expression was increased at early time
points after anti-CD3 and anti-CD28 stimulation, and lep-
tin mAb treatment did not alter Foxp3 protein amounts.
Conversely, at 12 hr, Treg cells that proliferated after leptin
mAb showed increased Foxp3 amounts when compared
to those activated with anti-CD3 and anti-CD28 alone
(Figure 4E). As expected, Foxp3 was undetectable in
CD4+CD25 T effectors after 1 hr of stimulation in all the
experimental conditions (Figure 4D), whereas at 12 hr,
there was a little expression of Foxp3 after anti-CD3 and
anti-CD28 stimulation either in the presence or in the ab-
sence of leptin mAb that did not reach statistical signifi-
cance (Figure 4E). All these data were confirmed by real-
time PCR (data not shown).
The Effect of Leptin Neutralization on ObR
and STAT3 Activation Pathway
The molecular effects of leptin mAb were studied at early
(1 hr) or late (12 hr) time points on highly purified human
Treg cells or effector CD4
+CD25 T cells, activated or not
with anti-CD3 anti-CD28.
We first analyzed the leptin-ObR-STAT3 biochemical
pathway: 1 hr and 12 hr cultures confirmed that in unsti-
mulated cells, the ObR was expressed at higher amounts
in Treg cells than in CD4
+CD25 T cells (Figures 3C, 5A,munity 26, 241–255, February 2007 ª2007 Elsevier Inc. 245
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Treg Cell Proliferation Controlled by LeptinFigure 4. Leptin-mAb-Induced Proliferation of Human Treg Cells Is IL-2 Dependent, and Foxp3 Expression Is Increased during
Proliferation
(A) Proliferation of CD4+CD25 effector T cells, Treg cells, and of both cell types in coculture in the presence or absence of leptin mAb and IL-2-
neutralizing mAb. The data are shown as mean ± SD (n = 5, *p < 0.01, **p < 0.05, white bars; *p < 0.001, black bars; *p < 0.01, gray bars).
(B) IL-2 secretion of CD4+CD25 effector T cells, Treg cells, and of both cell types in coculture in the presence or absence of leptin mAb and IL-2-
neutralizing mAb. The data are shown as mean ± SD (n = 5, *p < 0.01 and **p < 0.05, white bars; *p < 0.001, black bars; *p < 0.01, gray columns).
(C) Proliferation of Treg cells in the presence of either leptin mAb or recombinant IL-2 (left), stimulated or not with anti-CD3 and anti-CD28. The data are
shown as mean ± SD (n = 5, *p < 0.0001; **p < 0.01; ***p < 0.05). Addition of scalar doses of recombinant leptin to proliferating Treg cells (right) stim-
ulated with anti-CD3 and anti-CD28 in the presence of recombinant IL-2. The data are shown as mean ± SD (n = 5, NS, not significant).
(D) Immunoblot analysis of CD4+CD25 effector T cells and Treg cells in the presence or absence of leptin mAb, at 1 hr stimulation with anti-CD3 and
anti-CD28. The graph shows quantitation of Foxp3 with respect to tubulin. One representative out of five independent experiments is shown.
(E) Immunoblot analysis and flow cytometry plot of CD4+CD25 effector T cells and Treg cells in the presence or absence of leptin mAb, at 12 hr stim-
ulation with anti-CD3 and anti-CD28. The graph shows quantitation of Foxp3 with respect to tubulin. One representative out of five independent ex-
periments is shown (*p < 0.01, as compared with anti-CD3 and anti-CD28).and 5B). In vitro stimulation with anti-CD3 and anti-CD28
induced an upregulation of the ObR expression on both
cell types and was more evident at 1 hr than at 12 hr (Fig-
ures 3C, 5A, and 5B). Leptin neutralization on both Treg
cells and CD4+CD25 T cells further upregulated the ex-
pression of ObR, particularly at 1 hr, suggesting that leptin
blockade might induce a compensatory upregulation of its
receptor.
As readout of ObR activity, we measured phospho-
STAT3 (P-STAT3) amounts, because STAT3 is known to
participate in the intracellular signaling pathways of ObR
(reviewed in La Cava and Matarese, 2004). Activation of
CD4+CD25 T cells induced strong STAT3 phosphoryla-
tion at 1 hr and 12 hr and anti-leptin treatment reduced
the P-STAT3 amounts, particularly at 1 hr (Figures 5A
and 5B). Conversely, stimulation of Treg cells was not as-
sociated with a marked increase of P-STAT3, whereas
anti-leptin induced amounts of P-STAT3 at 1 hr and246 Immunity 26, 241–255, February 2007 ª2007 Elsevier Inc.12 hr comparable to those observed in proliferating
CD4+CD25 T cells (Figures 5A and 5B). Of note, at 1 hr,
CD4+CD25 T cells expressed both STAT3 spliced iso-
forms (Maritano et al., 2004)—STAT3a and STAT3b—
whereas Treg cells mainly expressed the STAT3a isoform.
This phenomenon was not as evident after 12 hr when the
two spliced isoforms were similar in both cell subsets,
suggesting that the tissue-culture conditions could induce
STAT3b in Treg cells, independently of the different type of
stimulation. Finally, in unstimulated or anti-CD3- and anti-
CD28-stimulated Treg cells, at both 1 hr and 12 hr, the
amounts of P-STAT3 were higher than those observed in
unstimulated CD4+CD25 cells, suggesting an increased
‘‘basal’’ leptin-mediated signaling in Treg cells. This result
could be secondary to higher basal expression of ObR
on Treg cells (Figures 1C, 3C, 5A, and 5B). No induction
of P-STAT3 was observed in Treg cells treated with leptin
mAb alone without TCR stimulation (Figure S5).
Immunity
Treg Cell Proliferation Controlled by LeptinFigure 5. Molecular Effects of Leptin Neutralization on Human Treg Cells
(A and B) Immunoblot for ObR, STAT3, and SOCS3 on CD4+CD25 T cells and Treg cells in the presence or absence of leptin mAb stimulated with anti-
CD3 and anti-CD28 at 1 hr and 12 hr, respectively. Graphs show quantitation of each specific protein. One representative out of five independent
experiments is shown.
(C and D) Immunoblot for ERK1/2, STAT1, and p27kip1. Graphs show quantitation of each specific protein. One representative out of five independent
experiments is shown.Immunity 26, 241–255, February 2007 ª2007 Elsevier Inc. 247
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Treg Cell Proliferation Controlled by LeptinWe also investigated in our system the expression of
suppressor of cytokine signaling 3 (SOCS3), a key nega-
tive regulator of cytokine signaling, including leptin (Kinjyo
et al., 2006; La Cava and Matarese, 2004). SOCS3 in anti-
CD3- and anti-CD28-stimulated CD4+CD25 T cells in-
creased markedly and was further increased by leptin
neutralization at 1 hr (Figure 5A). This finding inversely cor-
related with the corresponding P-STAT3 expression. At
a later time point (12 hr), SOCS3 was undetectable and
could be found at low amounts upon leptin neutralization
(Figure 5B). At 1 hr, SOCS3 in Treg cells was markedly
higher than in CD4+CD25 cells in all the experimental
conditions. Specifically, SOCS3 expression was high in
unstimulated Treg cells and increased after anti-CD3 and
anti-CD28 stimulation despite little STAT3 activation.
Treatment with anti-leptin, which induced P-STAT3, did
not alter the SOCS3 amounts (Figure 5A). At 12 hr, basal
SOCS3 expression was higher in the Treg cells than in
CD4+CD25 cells and was markedly reduced after anti-
CD3 and anti-CD28 stimulation. In conclusion, leptin
mAb treatment—which associates with STAT3 activation
in Treg cells—also induced SOCS3 expression (Figure 5B).
The Effect of Leptin Neutralization on Biochemical
Pathways Involved in T Cell Activation and Anergy
To evaluate whether leptin neutralization could affect T
cell activation and anergy, we studied tyrosine-phosphor-
ylation of the extracellular signal-regulated kinases 1 and
ERK2 (ERK1/2). Leptin neutralization in the presence of
anti-CD3 and anti-CD28 in CD4+CD25 T cells increased
ERK1/2 phosphorylation as compared to anti-CD3 and
anti-CD28 stimulation alone, particularly at 12 hr (Figures
5C and 5D). Treatment of Treg cells with anti-CD3 and
anti-CD28 did not induce phospho-ERK1/2 (P-ERK1/2),
confirming their anergic state. However, leptin mAb in-
duced high amounts of ERK1/2 tyrosine-phosphorylation
at both 1 hr and 12 hr, concomitantly with the induction
of Treg cell proliferation and a reversal of their hyporespon-
siveness (Figures 5C and 5D).
Moreover, we investigated whether leptin neutralization
could alter STAT1, another transcription factor whose ac-
tivity is required for the development and function of Treg
cells (Nishibori et al., 2004). We found that leptin neutrali-
zation did not affect STAT1 phosphorylation (P-STAT1) in
CD4+CD25 effectors at both time points. In contrast, P-
STAT1 was markedly induced in the leptin-neutralized
Treg cells (Figures 5C and 5D).
Last, we studied the modulation of the cyclin-depen-
dent kinase inhibitor p27 (p27kip1), a molecule involved in
the control of cell cycle, T cell anergy and known to block
the cell-cycle progression in Treg cells (Li et al., 2005; Wells
et al., 2001). p27kip1 was downmodulated by anti-CD3 and
anti-CD28 stimulation in CD4+CD25 effectors whereas
anti-leptin did not downmodulate p27kip1 expression at 1
hr and markedly increased its expression at 12 hr (Figures
5C and 5D), explaining, at least in part, the inhibition of
CD4+CD25 T cells proliferation induced by leptin neutral-
ization. In contrast, Treg cells showed elevated amounts of
p27kip1 before and after anti-CD3 and anti-CD28 stimula-248 Immunity 26, 241–255, February 2007 ª2007 Elsevier Inc.tion, confirming their anergic state associated with cell-
cycle arrest. Leptin mAb treatment induced degradation
of this molecule at both 1 hr and 12 hr, which could explain
reversal of their anergic state and subsequent proliferation
(Figures 5C and 5D).
Leptin Deficiency Promotes Proliferation
of Treg Cells in Mice
Treg cells, despite their in vitro hyporesponsiveness, can
expand in vivo in normal, nonlymphopenic hosts (Trenado
et al., 2003; Gavin et al., 2002). We used nonirradiated,
nonlymphopenic recipient mice to avoid a homeostatic ex-
pansion of the Treg cells that would occur in lymphopenic
hosts (Trenado et al., 2003; Gavin et al., 2002). The
in vivo proliferative capacity of Treg cells in anti-leptin-
treated wild-type (WT) mice versus control-Ig-treated
mice was tested with CFSE-labeled-CD4+ T cells from nor-
mal WT mice and by measuring the CFSE dilution in the
CD4+Foxp3+ cells (Figure 6A). Mouse Treg cells expanded
in vivo more robustly and earlier (day 4 and day 7 after
transfer) when adoptively transferred into leptin-neutral-
ized WT mice (Figure 6A). This result was confirmed by
adoptive transfer of CFSE-labeled-CD4+ T cells from nor-
mal WT mice into leptin-deficient ob/ob mice, in which the
Treg cells expanded more robustly and earlier (day 4 and
day 7 after transfer) when compared with cells transferred
into normal WT mice (Figure 6B). We also confirmed our
data in a transgenic antigen-specific system utilizing donor
mice carrying the (TcrAND)53Hed transgene (AND-TCR
Tg mice) expressing the clonotypic Va11.1/Vb3 TCR
chains, specific for the carboxy-terminal fragment of pi-
geon cytochrome c (PCC) (Kaye et al., 1989). Assessment
4 and 7 days after adoptive transfer revealed that trans-
ferred CFSE-labeled clonotypic AND-TCR Treg cells prolif-
erated more vigorously in ob/ob mice as compared with
normal WT controls (Figure 6C). This phenomenon was
reversed by recombinant leptin administration to leptin-
deficient ob/ob mice (Figure 6C). To avoid interference
of CD4+ T cell lymphopenia on the Treg cell expansion
in vivo, in the adoptive transfer experiments in ob/ob
mice, we utilized 6-week-old mice (in which the leptin de-
ficiency has not yet determined significant reduction of the
CD4+ T cell number). The in vivo results were also con-
firmed by CFSE dilution experiments gating on the
CD4+CD25+ Treg cells in both leptin-neutralized WT and
leptin-deficient ob/ob mice, respectively (Figures S6A
and S6C, respectively). Foxp3 expression was increased
in the Treg cells of the leptin-neutralized WT mice (Fig-
ure S6B). Finally, to confirm our data, we tested the ability
of Treg cells to expand in the presence of an anti-leptin re-
ceptor (anti-ObR)-blocking antibody. The data showed
a marked increase in the percentage of CD4+Foxp3+ Treg
cells in treated WT mice (data not shown).
Proliferative Potential and Functional Capacity of
Treg Cells from Leptin Receptor-Deficient Mice
We studied the in vitro proliferation and suppressive ca-
pacity of CD4+CD25 effectors and Treg cells from con-
genitally leptin-receptor-deficient db/db mice and normal
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(A) Proliferation measured as CFSE dilution of CFSE-labeled Treg cells obtained from WT mice and transferred into control (CTR)-Ig or mouse leptin
neutralizing Ab-treated WT mice. The histogram shows the percent of CFSE+ Treg cells (gated on CD4
+Foxp3+ cells) that had divided 4 and 7 days
after transfer. One representative out of three independent experiments with 3 mice per group is shown (*p < 0.01; **p < 0.001).
(B) CFSE dilution profile of CFSE-labeled Treg cells (gated on CD4
+Foxp3+ cells) obtained from WT mice and transferred into WT or leptin-deficient ob/
ob mice, 4 and 7 days after transfer. One representative out of three independent experiments with 3 mice per group is shown (*p < 0.01; **p < 0.001).
(C) CFSE dilution profile of PCC-specific CFSE-labeled AND-TCR Treg cells (gated on Va11.1
+/Vb3+Foxp3+ cells) adoptively transferred into WT,
ob/ob, and ob/ob treated with recombinant leptin, 4 and 7 days after transfer. One representative out of two independent experiments with
4 mice per group is shown (**p < 0.001; *p < 0.01).db/+ heterozygous controls (Figures 7A–7C). Stimulation
with anti-CD3 and anti-CD28 of CD4+CD25 effector T
cells from db/db mice was less effective in inducing prolif-
eration than stimulation on CD4+CD25 from db/+ mice
(Figure 7A). Conversely, in vitro stimulation of Treg cells
from db/db mice induced significantly higher proliferation
than that of Treg cells from db/+ heterozygous controls
(Figure 7B). These data suggested that the absence of
the ObR impaired the expansion of CD4+CD25 effectors
and enhanced the proliferative potential of Treg cells. The
ObR deficiency seemed to affect the proliferative potential
of the Treg cells rather than their qualitative or functional
activity, because Treg cells from db/db mice suppressed
the proliferation of CD4+CD25 T cells in a fashion similar
to that of Treg cells from db/+ control mice (Figure 7C),Imconfirming the finding that addition of exogenous leptin
did not alter the suppressive capacity of Treg cells in vitro
(Figure 2A).
Subsequent studies were performed analyzing antigen-
specific responses in an autoimmune disease model: the
in vitro proliferative capacity of Treg cells against the pan-
creatic autoantigen glutamic acid decarboxylase (GAD)65
was evaluated in autoimmune diabetes nonobese diabetic
(NOD/LtJ) mice versus leptin-receptor mutant NOD-
Leprdb5J/LtJ mice (Figure 7D; Lee et al., 2005). These re-
cently isolated ObR mutant mice display obesity, hyper-
phagia, and resistance to the development of pancreatic
b-islets infiltration (Lee et al., 2005). We found that after
5 days of splenocyte cultures, Treg cells from NOD-
Leprdb5J/LtJ proliferated more robustly against mousemunity 26, 241–255, February 2007 ª2007 Elsevier Inc. 249
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Cells Proliferative Potential, Does Not Al-
ter Their Suppressive Capacity, and Im-
pairs CD4+CD25 Proliferation
(A) Proliferation of CD4+CD25 effector T cells
from db/+ and leptin receptor-deficient db/db
mice stimulated with anti-CD3 and anti-
CD28. The data are shown as mean ± SD
(n = 5, *p < 0.001).
(B) Proliferation of Treg cells from db/+ and
db/db mice stimulated with anti-CD3 and
anti-CD28. The data are shown as mean ±
SD (n= 5, **p < 0.01).
(C) Proliferation of CD4+CD25 effector T cells
from db/+ mice in the presence of increasing
number of either db/+ or db/db Treg cells, stim-
ulated with anti-CD3 and anti-CD28. The data
are shown as mean ± SD (n = 5).
(D) CFSE dilution of Treg cells (gated on
CD4+Foxp3+ cells) from leptin receptor mutant
NOD-Leprdb-5J/LtJ mice stimulated with
mouse recombinant GAD65, after 5 days cul-
ture. One representative out of five indepen-
dent experiments is shown (*p > 0.01).GAD65 than Treg cells from NOD/LtJ females, suggesting
an increased autoantigen-specific proliferative potential
of the Treg cells from mice with impaired ObR signaling
(Figure 7D). In contrast, Foxp3 T cells from NOD-
Leprdb5J/LtJ proliferated significantly less than that of
NOD/LtJ controls (data not shown), suggesting that an ab-
sence of ObR impaired the expansion of Foxp3 effectors
and enhanced the proliferative potential of Treg cells.
Leptin-Deficient Mice Have Increased Numbers
of Treg Cells that Can Be Reduced
by Administration of Leptin
Mice with genetic deficiency of leptin (ob/ob) or leptin-
receptor (db/db) have reduced susceptibility to autoim-
munity (Matarese et al., 2001; Sanna et al., 2003; Sieg-
mund et al., 2004; Faggioni et al., 2000; Lee et al., 2005).
Treg cells play a central role in regulating autoimmunity
(Shevach, 2002; Sakaguchi, 2005), so we tested whether
genetic deficiency of leptin associated with effects on
Treg cells. A significant increase of the percentage of pe-
ripheral Treg cells was observed in ob/ob as compared
to WT (Figures S7A and S7B, respectively). Administration
of leptin reduced the elevated number of Treg cells in the
ob/ob mice to a number comparable to that found in the
WT mice (Figures S7A and S7B).
DISCUSSION
In this study we establish a unique link between Treg cells
and leptin by showing that leptin can modulate the hypo-
responsiveness and proliferation of Treg cells both in vitro
and in vivo. Freshly isolated human Treg cells express high
amounts of ObR and produce substantial amounts of lep-
tin that are responsible for an autocrine inhibitory loop that
constrains the expansion of Treg cells. Although leptin neu-
tralization inhibits the proliferation of effector CD4+CD25
T cells, this condition leads to an expansion of the Treg250 Immunity 26, 241–255, February 2007 ª2007 Elsevier Inc.cells, which maintain their suppressive phenotype in the
resting phase. The opposite effects of leptin blockade
on CD4+CD25 T cells and Treg cells associate with a dif-
ferential expression of intracellular leptin and cell-surface
ObR in the two cell subsets.
It must be noted that in our experimental system, the
culture media supplemented with human serum contained
low—albeit significant—concentrations of human leptin
(0.5–1 ng/ml in the 5% human serum [HS]/95% RPMI).
The contribution of HS-derived leptin versus Treg cell-de-
rived leptin was analyzed in cultures with three different
serum-free media—all tested for the absence of leptin.
The anti-leptin-induced expansion of the Treg cells in se-
rum-free conditions indicated that the Treg cell-derived
leptin was sufficient to act as negative signal for the ex-
pansion of the Treg cells. It is possible to speculate that
a leptin-mediated negative autocrine loop may operate
on Treg cells, because both freshly isolated and cultured
Treg cells stain positive for and secrete leptin. On the other
hand, the leptin present in the culture medium and se-
creted by the CD4+CD25 T cells could act as a positive
signal for T cell proliferation. These differential effects in-
duced by leptin could rely upon the different ObR levels
and leptin secretory capacity, which would ultimately af-
fect the intracellular signaling differentially.
Our Treg cells were cultured in medium supplemented
with 5% HS because fetal calf serum (FCS) is rich in bo-
vine leptin (10–20 ng/ml in RPMI 10% FCS) that is not neu-
tralized by human leptin mAb (data not shown). We also
found that 10% FCS abrogated the effects induced by hu-
man leptin mAb on human Treg cells (data not shown).
Therefore, it was crucial, for efficient leptin neutralization,
to avoid exposure to FCS for the ObR-expressing Treg
cells. The same issue has to be taken into account had
the Treg cells been isolated by positive selection and
thus undergone repeated steps of FCS exposure compro-
mising leptin neutralization. Moreover, we also noted that
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mAb (either by FACS or magnetic bead cell sorting) had
a reduced capacity to proliferate in vitro after leptin neu-
tralization when the anti-CD25 mAb was not removed
from the cell surface after isolation. The reasons for an in-
terference of the anti-CD25 mAb with leptin neutralization
process and Treg cell expansion are currently being inves-
tigated and might include an interference with IL-2 signal-
ing, a functional inactivation of the Treg cells by the anti-
CD25 mAb recently demonstrated (Kohm et al., 2006),
and an influence on the kinetics and the degree of leptin
secretion by the Treg cells. In any case, detachment of
the anti-CD25 mAb after cell isolation completely elimi-
nates possible problems of proliferation for the anti-
leptin-treated stimulated Treg cells (see Experimental
Procedures for details).
Previous experimental evidence suggests that the
growth, homeostasis, and function of the Treg cells is de-
pendent on IL-2 in vitro and in vivo (Setoguchi et al.,
2005; Fontenot et al., 2005). Our data also indicated that
leptin neutralization could induce IL-2 secretion by Treg
cells and that leptin mAb-induced-proliferation was IL-2
dependent. When comparing the efficiency of leptin
neutralization and IL-2 to expand Treg cells in vitro, we
observed that leptin mAb had a better efficiency than
recombinant IL-2 (as indicated by Treg cell proliferation
and number after 8 days culture). Conversely, addition of
increasing doses of recombinant leptin to the cell cultures
did not affect the IL-2-mediated proliferation of the Treg
cells, suggesting that the control of leptin on the expan-
sion of the Treg cells was independent and not overcome
by IL-2 signaling. McHugh et al. (2002) demonstrated
that cultures of Treg cells with neutralizing glucocorti-
coid-induced TNF receptor (GITR) mAb allowed the Treg
cells to respond to exogenous IL-2 in the absence of
TCR stimulation. We also tried to induce Treg cell prolifer-
ation in the absence of TCR stimulation by adding high
concentration of IL-2 and anti-leptin, but we found lack
of proliferation, indicating that anti-leptin-induced prolifer-
ation of the Treg cells needs concomitant TCR engage-
ment. This evidence was also confirmed at biochemical
level; anti-leptin alone in the absence of TCR stimulation
did not induce significant P-STAT3 levels in Treg cells.
Foxp3—the master gene for Treg cell development and
function (Sakaguchi, 2005)—was induced in leptin-neu-
tralized Treg cells at late time points (12 hr), supporting
the evidence that removal of leptin from culture medium
not only expanded the Treg cells but also allowed the main-
tenance of their phenotype. The phenomenon might pos-
sibly be ascribed to the increased IL-2 secretion induced
by leptin neutralization, because others have shown that
IL-2 is capable of upregulating Foxp3 expression in hu-
man Treg cells (Zorn et al., 2006).
At the molecular level, Treg cells expressed high levels of
ObR and of p27kip1 but no phosphorylation of ERK1/2 or
STAT1 and little phosphorylation of STAT3. In contrast,
leptin neutralization upon anti-CD3 and anti-CD28 stimu-
lation and Treg cell expansion was associated with a rapid
degradation of p27kip1 as well as a marked phosphoryla-tion of ERK1/2, STAT1, and STAT3 (phosphorylation of
STAT3 in Treg cells could be partly explained by both the
induction of the ERK1/2, which is known to phosphorylate
STAT3 independently of ObR [Quadros et al., 2004; Bar-
boza et al., 2004], as well as by the secretion of STAT3-ac-
tivating cytokines, i.e., IL-2 and IL-6 [Doganci et al., 2005]).
Recently, Zorn and collegues (Zorn et al., 2006) showed
that IL-2 upregulates Foxp3 expression in human Treg cells
through a STAT3-dependent mechanism, confirming that
induction of Foxp3 (in our case, during leptin neutraliza-
tion) may occur via a STAT3-dependent mechanism. In-
triguingly, CD4+CD25 T cells, after leptin neutralization,
showed an increase of p27kip1 associated with sustained
ERK1/2 phosphorilation—a phenotype often observed in
anergic T cells (Wells et al., 2001; Chen et al., 1999; Waic-
zies et al., 2005) and in effector T cells from mice treated
with anti-leptin antibodies during autoimmune encephalo-
myelitis (De Rosa et al., 2006). The fact that leptin neutral-
ization reduced the levels of STAT3 phosphorylation and
had little effect on STAT1 needs an explanation. This par-
tial effect on the ObR-STAT3-mediated signaling could be
ascribed to the fact that also other cytokines activate
STAT3 (Doganci et al., 2005). As such, removal of leptin
could only inhibit in part STAT3 phosphorylation. In this
context, it is interesting to note that SOCS3, a key nega-
tive regulator of STAT3-activating cytokines (Kinjyo
et al., 2006), also was differentially expressed in the Treg
cells and in the CD4+CD25 T cells. The regulation of
STAT3 signaling by SOCS3 in CD4+CD25 effectors was
biphasic, with a first peak at 1 hr and a rapid degradation
at 12 hr, as previously described (Wormald et al., 2006).
Leptin neutralization increased SOCS3 amounts concom-
itantly with a reduced phosphorylation of STAT3. This is
also consistent with the SOCS3 inhibition of IL-2 produc-
tion and T cell proliferation that we observed in our work
(Matsumoto et al., 2003). In Treg cells, SOCS3 was highly
expressed in basal conditions and markedly induced dur-
ing acute stimulation, in agreement with the anergic state
of the Treg cells and their reduced IL-2 secretion.
Our results indicate that leptin neutralization can ‘‘un-
lock’’ the hyporesponsiveness of Tregs via a rapid degra-
dation of the cell-cycle inhibitor p27kip1, associated with
the phosphorylation of ERK1/2. These biochemical events
would allow the Treg cells to enter the G1/S phase of the
cell cycle, induce IL-2 gene transcription, and, conse-
quently, reverse their anergic state (Li et al., 2005). Our
data also indicate that these changes associate with the
activation of STAT1 and STAT3, two transcription factors
related with cytokine signaling and proliferation of the Treg
cells (Doganci et al., 2005; Nishibori et al., 2004).
Incidentally, this study also describes a novel strategy
to expand human peripheral Treg cells, via leptin neutrali-
zation, although this approach needs to be further investi-
gated. Current strategies to expand Treg cells employ ex
vivo addition of cytokines to cultured cells during TCR
stimulation (Tang et al., 2004; Jiang et al., 2003). Because
neutralization of the leptin present in human serum of tis-
sue cultures and of leptin produced by Treg cells may be
sufficient to determine an expansion of the Treg cells, itImmunity 26, 241–255, February 2007 ª2007 Elsevier Inc. 251
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with exogenous IL-2, may improve the protocols of expan-
sion for Treg cells. We are currently investigating this pos-
sibility.
In vivo studies in leptin-deficient ob/ob mice show
higher percentage and absolute number of circulating
Treg cells. They can expand up to 90% in vivo in normal
nonlymphopenic hosts by day 28 after transfer (Trenado
et al., 2003). Adoptive transfer experiments of CFSE-la-
beled Treg cells from WT mice into leptin-deficient ob/ob
mice showed a significant in vivo expansion of Treg cells.
It is also noteworthy that chronic leptin deficiency allows
higher expansion of Treg cells when compared with acute
leptin neutralization induced by leptin Ab (the percentage
of proliferating Treg cells in ob/ob mice was always higher
than that observed in leptin-neutralized WT mice). Impor-
tantly, in vivo leptin neutralization also determined an
increased Foxp3 expression in the Treg cells, suggesting
maintenance of their suppressive phenotype after expan-
sion in vivo. Taken together, our data suggest that the
presence of ObR may be crucial in the control of the ex-
pansion of Treg cells because stimulated Treg cells from
db/dbmice proliferated better than Treg cells from controls
in vitro, whereas the suppressive capability of Treg cells
from db/db mice was similar to that of control mice.
Confirmation of the crucial function of ObR came in an
antigen-specific system of autoimmune diabetes in the
NOD/LtJ mouse with the finding of increased anti-
GAD65 proliferative response of Treg cells from ObR mu-
tants NOD-Leprdb5J/LtJ mice.
The fact that leptin can act as a negative signal for the
proliferation of Treg cells envisions new possibilities of
anti-leptin-based approaches for the immunotherapy of
conditions characterized by low numbers of Treg cells.
Leptin might act as an endogenous ‘‘sensing’’ factor link-
ing the environment (availability of nutrients) to circulating
Treg cell number. Because nutritional deprivation in-
creases susceptibility to infection and associates with
amelioration of clinical manifestations of autoimmunity
(Kuchroo and Nicholson, 2003; Payne, 2001), it will be im-
portant to address how this relates to the influence of lep-
tin on Treg cells and whether anti-leptin-based intervention
can be applied to tune cognate T cell responses in im-
mune regulation.
EXPERIMENTAL PROCEDURES
Purification, Cultures, and Assays with T Cells
Human CD4+CD25+ and CD4+CD25 T cells were purified from human
healthy donors PBL either by magnetic cell separation with the Dynal
CD4+CD25+ Treg Kit (Dynal-Biotech, Oslo, Norway) or by flow cytome-
try cell sorting (MoFlo high-performance cell sorter, Dako, Glostrup,
Denmark) and were rapidly cleaned with the Detach reagent (Dynal-
Biotech) from surface-bound CD25 mAb. Both magnetic beads-based
and flow cytometry-based purification techniques yielded a highly ex-
pressing CD25+ population (95%–98% pure by FACS analysis), 90%
of which expressed Foxp3. The Treg cells:effector ratio in the suppres-
sion experiments was 1:1. Cells were cultured (5 3 104 cells/well) in
round-bottom 96-well plates (Becton-Dikinson Falcon, Franklin Lakes,
NJ) with RPMI medium supplemented with 2 mM L-glutamine,
100 U/ml penicillin, 100 mg/ml streptomycin (all from Life Technologies252 Immunity 26, 241–255, February 2007 ª2007 Elsevier Inc.Inc., Gaithersburg, MD) and 5% AB human serum (Sigma-Aldrich, St.
Louis, MO). Cells were stimulated for 3 days in the presence of anti-
CD3/CD28 Dynabeads (0.1 bead/cell) (Dynal-Biotech). On the last
day, [3H]thymidine (0.5 mCi/well) (Amersham-Pharmacia Biotech, Co-
logno Monzese, Italy) was added to the cultures and cells harvested
after 12 hr. Radioactivity was measured with a b-cell-plate scintillation
counter (Wallac, Gaithersburg, MD).
For suppression experiments in the mouse, Treg cells were isolated
with the Regulatory T Cell Isolation Kit (Miltenyi Biotec, Gladbach, Ger-
many) and stimulated with Dynabeads mouse anti-CD3/CD28 (0.5
bead/cell; 5 3 104 cells/well). The Treg cells:effector ratio in the sup-
pression experiments was 1:2. Purified cells (98% pure by FACS anal-
ysis) were cultured in round-bottom 96-well plates (Becton-Dikinson
Falcon) with RPMI medium supplemented with 2 mM L-glutamine,
100 U/ml penicillin, 100 mg/ml streptomycin (Life Technologies) and
5% FCS or 5% mouse serum (Hyclone-Pierce, Rockford, IL). Cells
were stimulated for 3 days, labeled with [3H]thymidine (0.5 mCi/well)
for the last 16 hr of culture, and harvested similarly to what done for hu-
man T cell cultures.
Incorporation of Bromodeoxyuridine (BrdU) and FACS analysis were
performed in T cell cultures in serum-free medium (X-VIVO) with the
BrdU Flow Kit from BD-Pharmingen in accordance to the manufac-
turer’s instructions.
IL-2 Measurement
IL-2 measurement was done with the CTLL-2 cell line (kindly provided
by N. Davey, Imperial College London, UK) according to a previously
described method (Ng et al., 2001). Cells were maintained in culture
in supplemented RPMI medium with 10% FCS (Hyclone-Pierce) and
human recombinant (rh)-IL-2 (10 U/ml, Boehringer Mannheim, Man-
nheim, Germany). They were subcultured every 2 to 3 days. Cells
were rested in medium without IL-2 overnight prior to use in the assays.
Reagents, Leptin-Neutralizing Antibodies,
and Leptin Measurement
For in vitro blocking experiments, human leptin-neutralizing mAb (R&D
Systems, Minneapolis, MN) was used at a final concentration of 0.25 to
25 mg/ml; controls were irrelevant isotype-matched antibodies (Bio-
vendor Laboratory Medicine Inc., Brno, Czech Republic). Human re-
combinant leptin was purchased from R&D Systems. Human IL-2-neu-
tralizing mAb (MQ1-17H12) was from BD Pharmingen and was utilized
at final concentration of 5–10 mg/ml. FITC-anti-human-CD4 and PE-
anti-human-CD25 were from BD Pharmingen; the anti-human Foxp3
staining set was from eBiosciences (San Diego, CA). Recombinant
mouse GAD65 was purified from GAD65-producing cells that were
kindly provided by R. Tisch (University of North Carolina, Chapel Hill,
NC); recombinant GAD65 was tested for purity by SDS-PAGE and sil-
ver staining before the experimental use. The endotoxin content in the
preparations was below the detection limit (about 10 pg of endotoxin/
mg of protein) of the Limulus amebocyte lysate (LAL) method. Human
leptin-specific ELISA was purchased from R&D Systems and mea-
surements were performed according to the manufacturer’s instruc-
tions (Matarese et al., 2005). Serum-free media were RPMI (Life Tech-
nologies), HyQ-ADCF (Animal Derived Component Free, from
Hyclone-Pierce), and X-VIVO (BioWittaker).
Mice and In Vivo Experiments
6-week-old female leptin-deficient C57BL6/J-ob/ob (ob/ob),
C57BL6/J, leptin-receptor deficient C57BL/Ks-db/db (db/db), and
C57BL/Ks-db/+ lean controls (db/+) mice were purchased from Harlan
Italy s.r.l. (Corezzana, Italy); B10.Cg.Tg(TcrAND)53Hed/J (AND-TCR
Tg) PCC-specific transgenic mice were purchased from The Jackson
Laboratory (Bar Harbor, ME); NOD/LtJ and NOD-Leprdb5J/LtJ mutants
were kindly provided by E. Leiter from The Jackson Laboratory. Exper-
iments were conducted in accordance with the animal welfare guide-
lines under an approved protocol of the Istituto Superiore di Sanita`,
Roma, Italy. Mice were age-matched for individual experiments and
housed with a 12 hr light/dark cycle in the animal facility at the
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toneally twice daily for 10 days with mouse recombinant leptin (R&D
Systems) dissolved in 200 ml of PBS at a dose of 1 mg/g of body weight.
The mouse leptin-blocking antibody was produced in our laboratory
after immunization of C57BL/6J mice with mouse recombinant leptin
(R&D Systems) emulsified in complete Freund’s adjuvant (CFA) CFA
(Difco Laboratories, Detroit, MI); mouse leptin-specific antibodies (of
the IgM class) were affinity purified with recombinant mouse leptin
(R&D Systems) bound to AminoLink Plus Immobilization Gel (Amino-
Link Plus Immobilization Kit from Pierce, Rockford, IL) from serum
and ascites of immunized mice. Affinity-purified IgM were used as con-
trol (BD Pharmingen). WT mice were treated for 3 days either with
100 mg of control mouse IgM or with mouse leptin Abs intraperitoneally
in a total volume of 100 ml of PBS.
Adoptive transfer experiments were performed by labeling highly
purified (98% pure by FACS analysis) CD4+ T cells obtained from
C57BL6/J WT mice (cells were purified with the mouse CD4+ negative
isolation kit from Dynal) with the fluorescent dye CFSE (5-, 6-carboxy-
fluorescein diacetate succinimidyl ester) from Molecular Probes (Eu-
gene, OR) used at 1 mg/ml. In brief, 107 CFSE-labeled CD4+ T cells
were adoptively transferred into mice intravenously. 4 and 7 days later,
spleen cells were harvested from mice and stained with PE-anti-Foxp3
(eBioscience) and Cy-anti-CD4 (BD PharMingen). In experiments of
adoptive transfer performed with CFSE-labeled AND-TCR Tg CD4+ T
cells (98% pure), after 4 and 7 days, spleen cells were harvested
from recipient mice and stained with anti-clonotypic PE-anti-Va11.1
(RR8.1), biotynilated-anti-Vb3 (KJ25) (both from BD PharMingen),
and APC-anti-Foxp3 (eBioscience). Flow cytometric analysis of
CFSE dilution was performed by gating on CFSE+CD4+Foxp3+ cells
(in non-Tg mice) (Figures 6A and 6B) and on CFSE+Va11.1+/
Vb3+Foxp3+ cells (in AND-TCR Tg mice) (Figure 6C) with a FACScalibur
(Becton-Dickinson, San Diego, CA) and analyzed by Cell Quest soft-
ware (Becton-Dickinson).
Western Blots, Biochemical Analyses,
and Confocal Microscopy
Total cell lysates were obtained in 50 mM HEPES (pH 7.5), 250 mM
NaCl, 1 mM EDTA, 1.0% Triton X-100, 10 mM sodium fluoride,
1 mM sodium orthovanadate, and 2 mg/ml aprotinin, 2 mg/ml leupeptin,
and 2 mg/ml pepstatin. 50 mg of total proteins were subjected to SDS-
PAGE under reducing conditions. After electrophoresis, proteins were
transferred onto a nitrocellulose filter membrane (Protan, Schleicher &
Schuell) with a Trans-Blot Cell (Bio-Rad) and transfer buffer containing
25 mM Tris, 192 mM glycine, 20% methanol. Membranes were placed
in 5% nonfat milk in phosphate-buffered saline, 0.5% Tween 20 (PBST)
at 4C for 2 hr to block the nonspecific binding sites. Filters were incu-
bated with specific antibodies before being washed three times in
PBST and then incubated with a peroxidase-conjugated secondary
antibody (Amersham Biosciences). After washing with PBST, peroxi-
dase activity was detected with the ECL system (Amersham Biosci-
ences) or Femto (Pierce). The antibodies used were the following:
anti-p27Kip-1, anti-STAT3 and anti-phospho-STAT3 (Y705), anti-
STAT1 and anti-phospho-STAT1 (Y701) (Cell Signaling Technology,
Beverly, MA); anti-leptin, anti-ObR, anti-ERK 1/2, and anti-phospho-
ERK 1/2 (all from Santa Cruz Biotechnology Inc., Santa Cruz, CA);
anti-Foxp3 (eBioscience); anti-SOCS3 (Serotec Ltd, Kidlington, UK).
The filters were also probed with a tubulin antibody (Sigma) to normal-
ize the amount of loaded protein. Only for the human leptin western
blots, performed on a 15% SDS-PAGE gel to better visualize 16 kDa
leptin, normalization was performed against total ERK1/2. All filters
were quantified by densitometric analysis of the bands utilizing the
program ScionImage 1.63 for Mac (Scion Corporation, Frederick, MD).
Confocal microscopy was performed in parallel with proliferation
and biochemistry at 1 hr and 36 hr on 98% pure Treg cells and
CD4+CD25 cells. Cells were washed in PBS and 104 cells were
seeded on multitest slide (ICN Biomedicals Inc., Aurora, OH), air-dried
and fixed for 1 min in methanol, washed in PBS, permealized in PBS
containing 0.2% Triton X-100 for 3 min, and incubated in blocking so-Imlution (PBS 1% BSA) for 1 hr. Cells were then washed three times in
PBS and incubated overnight at 4C with primary antibodies (rabbit
polyclonal anti-leptin and mouse anti-ObR mAb, both from Santa
Cruz Biotechnology Inc.) diluted 1:100 in blocking solution, washed
in PBS, and incubated with the secondary antibody (goat anti-rabbit
488 and goat anti-mouse 543, both from Molecular Probes Inc.) for
1 hr at room temperature diluted 1:100 in blocking solution, washed
in PBS, and finally mounted in PBS/Glycerol 1:1. Immunofluorescence
analysis was performed with a confocal laser scanner microscope
Zeiss LSM 510. The wavelength of the Argon ion laser was set at
488 nm; that of the HeNe laser was set at 543 nm. Fluorescence emis-
sion was revealed by BP 505–530 band pass filter for Alexa Fluor 488
and by BP 560-615 band pass filter for Alexa Fluor 543. Double-stain-
ing immunofluorescence images were acquired simultaneously in the
green and red channels at a resolution of 1024 3 1024 pixels.
Statistical Analysis
Analyses were performed with the Mann-Whitney U-test for unrelated
two-group analyses and the Kruskal-Wallis ANOVA test for three or
more group analyses with the StatView software (Abacus Concepts
Inc., Cary, NC). Results are expressed as mean ± SD. p values <
0.05 were considered statistically significant.
Supplemental Data
Seven Supplemental Figures can be found with this article online at
http://www.immunity.com/cgi/content/full/26/2/241/DC1/.
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